Archives of Industrial Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Perspective - Archives of Industrial Biotechnology (2023) Volume 7, Issue 5

Bioconjugation in molecular imaging from fluorescence to MRI.

Philip Freis *

Department of Chemistry, University of British Columbia, Vancouver, Canada

*Corresponding Author:
Philip Freis
Department of Chemistry, University of British Columbia, Vancouver, Canada

Received: 25-Sep-2023, Manuscript No. AAAIB-23-116971; Editor assigned: 29-Sep-2023, PreQC No. AAAIB-23-116971(PQ); Reviewed:11-Oct-2023, QC No. AAAIB-23-116971; Revised:21-Oct-2023, Manuscript No. AAAIB-23-116971(R); Published: 27-Oct-2023, DOI:10.35841/ aaaib -7.5.170

Citation: Freis P. Bioconjugation in molecular imaging from fluorescence to MRI.2023;7(5):170

Visit for more related articles at Archives of Industrial Biotechnology




Molecular imaging has revolutionized our understanding of biology and medicine by allowing us to visualize and study biological processes at the molecular level in living organisms. One of the key techniques that have enabled this progress is bioconjugation, a versatile tool that connects specific biomolecules with imaging agents. Bioconjugation has paved the way for a range of imaging modalities, from fluorescence to magnetic resonance imaging (MRI), offering unprecedented insights into cellular functions, disease processes, and drug development. Bioconjugation is a multidisciplinary field at the intersection of chemistry, biology, and medicine. It involves the covalent or non-covalent attachment of a biomolecule, such as a protein or nucleic acid, to an imaging agent, which can be a fluorophore, a contrast agent, or a nanoparticle. The goal of bioconjugation is to label specific molecular targets in cells or tissues, making them visible and detectable with imaging techniques [1].

Fluorescence imaging is one of the earliest and most widely used bioimaging techniques. It relies on the emission of fluorescent light by certain molecules, known as fluorophores, when they are excited by specific wavelengths of light. Bioconjugation plays a crucial role in fluorescence imaging by attaching fluorescent labels to biomolecules of interest. One of the most common bioconjugation strategies in fluorescence imaging is the use of antibodies or antibody fragments conjugated to fluorophores. This enables the specific targeting of antigens in cells and tissues. For example, green fluorescent protein (GFP) and its variants have been widely used for visualizing proteins and organelles in live cells. The advent of super-resolution microscopy techniques has further enhanced the spatial resolution of fluorescence imaging, allowing researchers to explore the nanoscale world of molecular interactions [2].

PET is a powerful molecular imaging technique that utilizes bioconjugation to attach radioactive isotopes to biologically active molecules. PET tracers, such as [18F]FDG (fluorodeoxyglucose), are used to monitor metabolic processes in vivo. In this technique, a radioactive isotope is attached to a biologically active molecule, and its distribution can be visualized using PET scans. Bioconjugation is crucial in the development of PET tracers, ensuring that the radioactive label is selectively delivered to the target tissue or organ of interest [3].

SPECT is another nuclear medicine imaging technique that relies on bioconjugation. Similar to PET, SPECT uses radiolabeled compounds to visualize specific molecular targets. Bioconjugation ensures that the radiotracer binds to the desired biomolecule, allowing for precise imaging of various physiological processes, such as blood flow, receptor distribution, and cellular function. While bioconjugation has been instrumental in advancing fluorescence and nuclear imaging techniques, it has also found a crucial application in magnetic resonance imaging (MRI). MRI is a non-invasive imaging modality that provides high-resolution anatomical images and functional information. However, it lacks the sensitivity to detect specific molecular events directly. Bioconjugation has addressed this limitation by introducing targeted contrast agents for molecular MRI. Contrast agents in MRI work by altering the relaxation times of water molecules in tissues, resulting in differences in signal intensity. Bioconjugation is used to attach these contrast agents to specific biomolecules, allowing them to be delivered to the site of interest. This targeted approach enhances the sensitivity and specificity of MRI for detecting and characterizing diseases at the molecular level [4].

While bioconjugation has significantly advanced molecular imaging techniques, there are several challenges and ongoing developments in this field. One major challenge is ensuring the stability and specificity of bioconjugates. The choice of bioconjugation chemistry, the linker molecules used, and the attachment site on biomolecules can all influence the stability and functionality of the conjugates. Another challenge is the potential toxicity of contrast agents used in molecular MRI. Researchers are continually working on the development of safer and more biocompatible contrast agents. Additionally, the regulatory approval process for new bioconjugates used in clinical imaging requires rigorous testing to ensure their safety and efficacy. The future of bioconjugation in molecular imaging holds exciting possibilities [5].


Bioconjugation has revolutionized molecular imaging by enabling the specific labeling of biomolecules and the development of targeted imaging agents. From fluorescence to MRI, bioconjugation plays a vital role in visualizing and understanding molecular processes in living organisms. As technology continues to advance, bioconjugation will likely contribute to even more powerful and precise molecular imaging techniques, ultimately leading to better diagnostics, therapeutics, and our overall understanding of biology and disease.


  1. Dumont MF, Hoffman HA, Yoon PR, et al. Biofunctionalized gadolinium-containing prussian blue nanoparticles as multimodal molecular imaging agents. Bioconjugate chemistry. 2014;25(1):129-37.
  2. Indexed at, Google Scholar, Cross Ref

  3. Manning HC, Goebel T, Thompson RC, et al. Targeted molecular imaging agents for cellular-scale bimodal imaging. Bioconjugate chemistry. 2004;15(6):1488-95.
  4. Indexed at, Google Scholar, Cross Ref

  5. Kairdolf BA, Qian X, Nie S. Bioconjugated nanoparticles for biosensing, in vivo imaging, and medical diagnostics. Analytical chemistry. 2017;89(2):1015-31.
  6. Indexed at, Google Scholar, Cross Ref

  7. Mather S. Molecular imaging with bioconjugates in mouse models of cancer. Bioconjugate Chemistry. 2009;20(4):631-43.
  8. Indexed at, Google Scholar, Cross Ref

  9. He X, Gao J, Gambhir SS, et al. Near-infrared fluorescent nanoprobes for cancer molecular imaging: Status and challenges. Trends in molecular medicine. 2010;16(12):574-83.
  10. Indexed at, Google Scholar, Cross Ref


Get the App